The immunotherapeutic strategy for melanoma consists of either authorized approaches such as checkpoint inhibitors, cytokine administration (interleukin-2 (IL-2) or interferon) or experimental treatments including adoptive T cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) [2], and active vaccination. This evidence concerns the gene IL2 and neoplasm.